On November 10, 2026 The U.S. Food and Drug Administration (FDA) reported it has approved the Promega OncoMate MSI Dx Analysis System designed to identify patients with microsatellite high (MSI-H) solid tumors as a companion diagnostic designed for KEYTRUDA, Merck’s (known as MSD outside the U.S. and Canada) anti-PD-1 therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in solid tumor tissue. MSI status can be used to inform treatment decisions and support precision oncology strategies.
"This approval reflects our dedication to providing meaningful diagnostic advances, developed to the highest quality and regulatory standards," says Alok Sharma, Global Clinical Market Director at Promega. "Our test connects patients with the therapy most likely to help them, working alongside our pharmaceutical collaborators and the clinicians who use the result."
This approval was supported through a collaboration with Merck, which markets KEYTRUDA. Together, the companies are working to advance personalized medicine and expand access to diagnostics that enable informed therapeutic choices.
OncoMate MSI Dx Analysis System was previously cleared by the FDA as the first PCR-based molecular diagnostic for identifying colorectal cancer patients who may benefit from additional testing to diagnose Lynch syndrome. It is also an approved companion diagnostic to identify patients with microsatellite stable (MSS) endometrial carcinoma who may benefit from treatment with KEYTRUDA plus LENVIMA (Lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. These approvals apply to the United States and its territories. Promega MSI technology is also CE-marked under IVDR in the European Union and has received approval from China’s National Medical Products Administration (NMPA) as a companion diagnostic to identify patients with MSI-H solid tumors who may benefit from treatment with KEYTRUDA.
KEYTRUDA is indicated for adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient cancer who have progressed following prior treatment and who have no satisfactory alternative treatment options. KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
(Press release, Promega, NOV 10, 2026, View Source [SID1234674593])